Decoglurant
Clinical data
ATC code
  • none
Legal status
Legal status
  • Development terminated
Identifiers
  • 5-({7-(Trifluoromethyl)-5-[4-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl}ethynyl)-2-pyridinamine
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
Chemical and physical data
FormulaC21H11F6N5
Molar mass447.344 g·mol−1
3D model (JSmol)
  • C1=CC(=CC=C1C2=NC3=C(C=NN3C(=C2)C(F)(F)F)C#CC4=CN=C(C=C4)N)C(F)(F)F
  • InChI=1S/C21H11F6N5/c22-20(23,24)15-6-4-13(5-7-15)16-9-17(21(25,26)27)32-19(31-16)14(11-30-32)3-1-12-2-8-18(28)29-10-12/h2,4-11H,(H2,28,29)
  • Key:DMJHZVARRXJSEG-UHFFFAOYSA-N

Decoglurant (INN) (code name RG1578, RO4995819) is a negative allosteric modulator of the mGlu2 and mGlu3 receptors which was under development by Roche for the adjunctive treatment of major depressive disorder.[1][2] Decoglurant progressed as far as phase II clinical trials[1][2] but was ultimately discontinued from further development due to disappointing efficacy results.[3][4]

See also

References

  1. 1 2 "Roche – Pipeline". 2014. Retrieved 2014-08-01.
  2. 1 2 "Roche Group Development Pipeline" (PDF). 2014. Archived from the original (PDF) on 2014-08-08. Retrieved 2014-08-01.
  3. ↑ "Roche – Pipeline" (PDF). 2015. Archived from the original (PDF) on 2015-05-01. Retrieved 2015-05-14.
  4. ↑ Lawrence J (March 2015). "The Secret Life of ketamine". The Pharmaceutical Journal. 294 (7854/5).
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.